Abstract Regenerative medicine has the potential to drastically change the field of health care from reactive to preventative and restorative. Exciting advances in stem cell biology and cellular reprogramming have fueled the progress of this field. Biochemical cues in the form of small molecule drugs, growth factors, zinc finger protein transcription factors and nucleases, transcription activator-like effector nucleases, monoclonal antibodies, plasmid DNA, aptamers, or RNA interference agents can play an important role to influence stem cell differentiation and the outcome of tissue regeneration. Many of these biochemical factors are fragile and must act intracellularly at the molecular level. They require an effective delivery system, which can take the form of a scaffold (e.g., hydrogels and electrospun fibers), carrier (viral and nonviral), nano-and microparticle, or genetically modified cell. In this review, we will discuss the history and current technologies of drug, protein, and gene delivery in the context of regenerative medicine. Next, we will present case examples of how delivery technologies are being applied to promote angiogenesis in nonhealing wounds or prevent angiogenesis in age related macular degeneration. Finally, we will conclude with a brief discussion of the regulatory pathway from bench to bedside for the clinical translation of these novel therapeutics.
Introduction
The term "regenerative medicine" was coined in 1999 by William Hasetine, and was predated by the term of tissue engineering, which creates organs or tissues in vitro [1] . Regenerative medicine employs aspects of tissue engineering, stem cell therapy, genetic engineering, materials science, drug delivery, and biomedical engineering to develop therapies that maintain and restore the normal function of damaged, diseased, or deficient tissues or organs. This field has increasingly captured the imagination of scientists and laymen alike because of the promise of restoring the functions of damaged tissues or organs in vivo. However, the excessive cost of commercialization and difficulties in the regulatory approval of complex therapeutic systems have delayed the translation of these therapies from bench to bedside [2] . Two of the oldest and most successful regenerative medicine companies are Organogenesis (specializing in wound healing and regeneration) and Medtronic (specializing in cardiac and vascular diseases, diabetes, and neurological and musculoskeletal conditions). However, many companies have failed on the path to clinical translation, possibly due to the difficulty of developing a business model that can maximize the commercial impact of cell-based therapies [3] .
Despite the difficulties surrounding commercialization of cell-based therapies, bone marrow-derived stem cells have been used successfully in the clinic for bone, cartilage, spinal cord, cardiac, and bladder regeneration [2] . This field has been fueled by exciting advances in stem cell biology, particularly the recent discovery that adult cells can be reprogrammed into pluripotent stem cells [4] or directly into cells of another lineage [5] . Although various forms of stem cells (embryonic, progenitor, induced, or transdifferentiated) often play a central role in regenerative medicine, biochemical cues in the form of drug, protein, or nucleic acid can provide a supportive or even decisive role in determining the fate of the stem cells and the eventual outcome of the tissue regeneration. These soluble therapeutics alone can also in some cases achieve a regenerative outcome, by acting on the resident cells at the tissue site. For example, heparan sulfate is a form of regenerative therapeutic that can be administered to recruit endogenous growth factors at the site of injury to initiate repair due to the specific interactions of heparan sulfate with many growth factors [6] . Readers are referred to recent excellent reviews on stem cell based-regenerative medicine [7] [8] [9] [10] . This review will focus only on the role of soluble therapeutics, and their effective delivery, in advancing regenerative medicine.
Many therapeutics relevant to regenerative medicine are delicate growth factors and nucleic acids, often with short half-lives and requiring intracellular delivery. Effective drug delivery systems (DDS) are needed to realize their potential. Fortunately, needs for other therapies have already stimulated the development of drug delivery technologies for decades. One of the pivotal discoveries that stimulated protein delivery development was the characterization of restriction endonucleases. This allowed for mapping of DNA and the invention of recombinant technology, where a foreign protein could be expressed in bacterial cells [11] . This led to the commercial production of proteins in 1982, when the Food and Drug Administration (FDA) approved the first recombinantly generated protein (insulin). The approval of insulin brought with it a need for delivery systems that would increase the half-life and sustain the release of proteins [12] . At the time that the methodology for protein delivery was being established, investigators began to work on gene delivery. In 1989, the first human gene transfer was achieved [13] , and shortly thereafter, the first gene therapy for severe combined immunodeficiency was developed in 1990 [14] . The development of nonviral gene delivery systems has been stimulated by the realizations that (1) viral gene transfer will hinder eventual clinical translation, and (2) gene transfer relying on naked plasmid DNA is woefully inefficient. The sophistication of drug delivery has since progressed from macroscopic , to microscopic , and finally nanoscale (1990-present) delivery systems (Fig. 1) .
Delivery is considered the single toughest barrier to clinical translation of protein-and gene-based therapeutics. In this article, we will discuss the current state of small molecule drug delivery for regenerative medicine, as well as the most promising peptidic and nucleic acid-based drugs that we expect to be at the forefront of regenerative therapeutics translating into clinical use. From there, we will examine delivery vehicles commonly used to extend the lifetime, circulation, and specificity of these soluble factors. As a case example, we will consider arguably one of the most important issues in regenerative medicine: the clinical progress being made by delivery of soluble factors to promote or inhibit angiogenesis. Delivery of soluble factors using synthetic or biologic DDS presents a new wave in regenerative therapeutics moving towards clinical translation. As an understanding of the regulatory pathway between developmental research and the clinic is critical for clinical translation, we will conclude with a brief discussion of the pathway to the clinic for regenerative therapeutics. (or low molecular weight drugs), proteins (polypeptides), and nucleic acids (genes) are being developed to mimic these cues and drive regeneration. Polypeptides have been delivered to drive regeneration in the form of growth factors [15] , zinc finger protein transcription factors [16] , zinc finger nucleases, transcription activator-like effector nucleases, and monoclonal antibodies [17] . Nucleic acids have had success when delivered in the form of cDNA [18] , RNA interference (RNAi) [19] , and aptamers [20] . The definitions, uses, positive, and negative attributes of these soluble factors as tools for regenerative medicine will be examined in this section.
Small molecule drugs
Regenerative therapeutics involving small molecule drugs (SMDs) is a recent area of research, with more than five times as many publications on their use since 2008 than in the 10 years prior. SMDs that influence cell behavior are being studied from existing drug libraries, as well as in novel formulations [21] . Select start-up companies like ChemRegen are focusing developing novel SMDs for cardiac muscle regeneration therapies [21] . Current research of SMDs targeting regenerative medicine focuses primarily on compounds that stimulate stem cell differentiation [22] and somatic cell behavior [23] such as proliferation, differentiation, and intracellular signaling to drive and direct tissue regeneration. SMDs for regenerative medicine could have a massive translational impact because they are well understood by the FDA and pharmaceutical drug companies, and the machinery to safely manufacture and distribute SMDs is already in place around the world. SMDs are typically far less expensive for consumers, have a longer shelf life, and are less complicated than protein, nucleic acid, or cellularbased therapies. However, the identification and optimization of new SMDs is a slow, laborious, and costly process, averaging $1.8 billion in company spending to bring a single new drug to the market [24] . Because of the cost associated with drug development, previously discovered drugs are being studied for their regenerative effects. For example, rolipram, an antiinflammatory and phosphodiesterase 4 inhibiting SMD, had been previously shown to improve spinal cord regeneration in small doses, but had adverse effects when delivered in larger doses [25] . The incorporation of this SMD into a microfibrous patch for continuous local delivery generated greater functional and anatomical recovery in rats following spinal cord injury in low dose groups and resulted in reduced survival rates in high dose groups [26] . Another previously developed SMD, valproic acid (VPA), had been shown to promote cortical neuronal growth in vitro [27] , and was recently shown to enhance sciatic nerve regeneration in rats when delivered locally within silicone tubes [28] . Rats treated with VPA showed a significant decrease in sciatic nerve index as well as increased motor-nerve conduct velocity, amplitude of activity potential, regenerated axon number, and thickness of myelin sheath compared with controls, which received saline injection [28] . These works highlight the need for reliable local DDS in the use of SMDs for regenerative applications.
Protein-based therapeutics
Recombinant DNA technology has enabled protein-based molecules such as growth factors, zinc finger protein transcription factors, zinc finger nucleases, transcription activatorlike effector nucleases (TALENs), and monoclonal antibodies to be developed and used as drugs [29] . Recombinant DNA techniques are used to clone, express, and purify any protein with a known DNA sequence in vitro using cost-effective methods [30] . Since the first FDA-approved pharmaceutical recombinant protein entered the market in 1980, the biotechnology industry has grown substantially [31] . Currently, 25 % of commercial pharmaceutical sales are biopharmaceuticals, with sales in 2010 US exceeding $100 billion USD [32] . Protein-based therapeutics are successful in regenerative applications because they can mimic, activate, or inhibit endogenous pathways, helping the body to heal. Bioengineers can mimic biochemical cues in nature by developing recombinant proteins and engineering their delivery. However, the use of protein-based drugs for regenerative therapeutics is limited by their propensity for instability in vitro and in vivo, presenting a challenge for handling, and implying a need for repeated doses over time and the possibility for unwanted side effects. Cost of development is also high; the estimated research and development cost for a single biopharmaceutical approved molecule is estimated around $1.3 billion [33] .
Growth factors
The term "growth factor" encompasses a range of signaling proteins that influence cellular processes including migration, proliferation, and differentiation (Fig. 2a) . Growth factors exist in the body as soluble molecules secreted by cells, bound to the extracellular matrix (ECM), or cleaved and released from the ECM by enzymes. Growth factors interact with cells through transmembrane receptors to naturally regulate tissue regeneration. Vascular endothelial growth factor (VEGF) has been shown to be a key regulator of blood vessel formation, and as such been widely studied for angiogenesis. However, bolus administration of naked VEGF-A leads to leaky blood vessels that can be toxic to cells and result in hypotension in vivo [34] . Intracoronary infusion of naked VEGF for treatment of ischemia for vascular angiogenesis showed success in animal trials and went through phase II clinical trials, but failed to show success compared to control [35] . This could have occurred because VEGF has a short half-life of 90 min in vivo [36] and is cleared from the body rapidly (within 8 h) [37] . Unfortunately, the field has a lot of progress to make before GF therapeutics reach clinical use, since their failure in phase II and III clinical trials has become more common than their success. Growth factors typically demonstrate efficacy above certain concentrations, can be toxic in excess, are subject to enzymatic cleavage, and have short half-lives. As such, controlled release technologies that can achieve local and sustained delivery are needed facilitate their clinical success.
Zinc finger protein transcription factors and TALENs
Zinc finger proteins (ZFPs) are named because of their shape, which is created by a short stretch of amino acid residues wrapped around a zinc atom in the shape of a finger (Fig. 2b) . ZFPs are the most common DNA-binding proteins in eukaryotes; their main role is in the recognition of specific DNA sequences. ZFPs are modular constructs with each binding domain recognizing 3-4 DNA base pairs. Several binding domains can be stitched together to recognize a unique sequence of DNA. Artificial ZFPs are commonly designed with six binding domains to recognize a unique sequence in the human genome of 18-19 base pairs. However, similar to other protein cues, the in vivo half-life of ZFPs is on the order of hours [38] .
ZFPs can bind to a specific DNA stretch and physically block transcription from occurring. The addition of an effector domain to the ZFP construct gives another level of modularity for transcription activation or repression of any endogenous gene, hence the term zinc finger proteintranscription factor (ZFP-TF). ZFP-TFs have a unique design advantage over most other DNA-binding motifs, in that they do not have to bind to target DNA as dimers. Because of their small size, multiple ZFP-TFs can be included in one gene transfer vector, and their encoding DNA delivered using viral or nonviral vectors. ZFP-TFs have been mainly studied for the regulation of genes involved in cancer [39] . Perhaps, the most exciting use of ZFP-TFs is their ability to activate or repress any endogenous gene, theoretically expressing all of its splice variants [40, 41] . ZFP-TFs have been shown to preserve hindlimb grip strength and improve functional outcomes for treatment of ALS in a rat model [16] and to increase VEGF mRNA, capillary density, and proliferating cells in ischemic tissue in rabbits [42] . ZFP-TFs are typically generated in random libraries and selected for multiple ZFPs can be generated to recognize a unique sequence in the genome (b). Monoclonal antibodies recognize specific antigens within the body; once bound to their target, they can either physically inactivate it or recruit immune cells to destroy it (c) specificity using phage display. Despite the well-described steps for protein production and purification, ZFP-TF production remains a high-cost and time-consuming process that makes their translation into clinical medicine difficult. Zinc finger nucleases (ZFNs) are similar to ZFP-TFs in their structure but work as restriction enzymes for genome editing, rather than as transcription factors. ZFNs are generated by fusing a ZFP DNA-binding domain to a nonspecific DNA-cleavage domain [43] . ZFNs have been used to genetically modify patient-derived induced pluripotent stem cells (iPSCs) (see Sect. C.4.1) for the treatment of sickle-cell anemia and Parkinson's disease [44, 45] . ZFN-modified autologous T cells are currently in clinical trials for HIV treatment [46] . ZFNs face the same barriers to translation as ZFP-TFs, specifically high cost and difficulty of generation.
TALENs have recently emerged as an alternative to ZFNs for genome editing. Although in their infancy, TALENs have been suggested to cleave DNA with similar efficiency as zinc finger nucleases, but boast simplistic design methods [47] . Because of their ease and low-cost production, TALENs are likely to join, or even surpass, ZFP-TFs as regenerative therapeutics over the next decade. Both of these classes of nucleases are being used as novel methods to generate cell populations for drug screening [48] , and offer hope of modified cellular therapies for patients with genetic disorders that are resultant of small genetic abnormalities, such as sicklecell anemia. However, both ZFNs and TALENs can cause unwanted mutation in the genome, limiting their use to applications outside the body, such as modified cellular therapeutics and generation of disease modeling methods [49, 50] .
Monoclonal antibodies
Monoclonal antibodies (mAB) are large proteins naturally produced by B cells in the immune system for the recognition of specific antigens in the body. Each mAB binds to a specific epitope on an antigen and either physically inactivates it or recruits immune cells to destroy it (Fig. 2c) . Humanized mABs are a rapidly growing category of targeted proteinbased therapeutics. Due to their mechanism of action, therapeutic mABs are used to inactivate pathways associated with disease states. Humanized mABs are in clinical trials for treatment of arthritis, cancer, immunological diseases, and infectious diseases [51] . Ranibizumab is a recombinant mAB that neutralizes all active forms of VEGF-A. It is used clinically for treatment of the excessive neovascularization of the macula associated with age-related macular degeneration (AMD) [17] . Since its FDA approval in 2006, ranibizumab has shown success in slowing the vision loss associated with AMD in up to 96 % of patients [52] . In vivo mABs bind to protective receptors on cells, elongating their clinical half-life up to 4 weeks; however, their large size causes them to distribute slowly into the tissue [53] . Clinically, mABs are administered intravenously, intramuscularly, or subcutaneously every 3-4 months [54] . Unfortunately, complications such as cytokine release syndrome and immunogenicity are still concerns for these mAB therapeutics [55] .
Nucleic acid therapeutics
There are several forms of nucleic acids which are delivered for regenerative medicine; the three most prominent are plasmid complementary DNA (cDNA), small RNA, and aptamer. cDNA encoding for a therapeutic gene is delivered directly to cells in vivo or in vitro, so that they will express that gene or protein of interest. Methods of DNA delivery to cells will be discussed in the carriers section. Small RNAs are used to regulate gene expression in vivo by controlling protein transcription and translation at the mRNA level, this process is known as RNAi. Aptamers are similar to mABs in that they bind and inhibit a specific biological target, such as an enzyme or receptor, but they are generated by chemical methods. Nucleic acid therapeutics act at the molecular level; however, their intracellular delivery is inefficient because they will not passively cross the plasma membrane of cells due to their size and negative charge.
Gene delivery-cDNA cDNA are DNA sequences that are complementary to mRNAs encoding for a specific gene and are used to introduce genes to cells. cDNA delivery is a highly versatile and widely used method for regenerative therapeutics, as cells can be modified to express any gene of interest. cDNA delivery encoding for insulin-like growth factor-I and keratinocyte growth factor has successfully accelerated endogenous VEGF and collagen type IV expression, neovascularization, and epidermal regeneration of dermal wounds in a rat model [18] . The greatest setbacks to the therapeutic use of cDNA are the delivery method and the risk of accidental DNA insertion into an important region in the human genome. Rather than delivering cDNA to regulate mRNA, direct delivery of mRNA has been explored as a gene delivery tool for cell modification [56] . Since mRNA will not integrate into the genome as DNA can, even when delivered nonvirally, it offers a gene delivery option free of the threat of insertional mutagenesis.
RNAi
RNAi takes advantage of the ability of small RNA to regulate gene expression. Small RNAs are endogenous single-or double-stranded nucleic acid sequences between 21-24 nucleotides in length that do not code for proteins, but rather inhibit mRNA that do. Small RNAs present a unique opportunity to control protein transcription and translation in the body. Many small silencing RNAs have been discovered recently. Those used in regenerative therapeutics include small interfering RNA (siRNA) and microRNAs (miRNA), both mediate the downregulation of gene expression. siRNAs bind to specific mRNAs and label them for nuclease destruction, while miRNA attach to the encoding mRNAs and physically prevent them from being translated to proteins. SiRNAmediated endogenous gene silencing in mammalian cells was first demonstrated in 2001 [57] . Current research directs siRNA against mRNA encoding proteins involved in degenerative diseases and vascularization of cancerous tumors [58] . siRNA is currently in clinical trials for use against VEGF, and its receptor (VEGFR-1) to treat AMD [59] . These trials involve direct injection of siRNA targeted at genes for VEGF and VEGFR-1 into the macula and have shown some therapeutic treatment potential in their inhibition of the excessive vascularization of the eye that leads to AMD. siRNA has also been used to induce therapeutic angiogenesis in a murine diabetic wound model by inhibiting the hypoxia-inducible factor (HIF)-1 inhibitor prolyl hydroxylase domain 2 (PHD2) [19] . In this study, the inactivation of PHD2 led to the stabilization of HIF-1 and subsequent production of VEGF and fibroblast growth factor 2 in the wound bed, leading to improved closure time in diabetic wounds. The main barrier against the use of RNAi therapeutics in regenerative medicine is the delivery because they are rapidly cleared in vivo, are not tissue specific, and their negative charge and size prevents passive endocytosis across the cellular membrane. While RNAi is heralded for its myriad of clinical uses, most of those fall outside the realm of regenerative medicine, focusing rather on disease remediation [60] .
Aptamers
DNA and RNA aptamers are nonbiological oligonucleotides that bind to specific protein targets. Aptamers bind to their target with high affinity and specificity and work by inhibiting its action. Aptamers for a specific target are generated in vitro by a selection process called systemic evolution of ligands by exponential enrichment (SELEX), where a random library of sequences (20-100 residues in length) is screened for aptamer-target conjugation [61] . Using the SELEX process, aptamers can be selected that only work in specific physiological conditions such as pH, salt concentration, and temperature. Therapeutic aptamers are primarily delivered as systemic anticoagulants and cancer therapeutics [62] . However, aptamers have also had regenerative success in the treatment of AMD [20] . Pegaptanib, an anti-VEGF RNA aptamer marketed under the drug name Macugen, was approved by the FDA in 2004 and has been used clinically for the treatment of all types of AMD [63] . Aptamers are generated by chemical processes resulting in little batch-to-batch variation and are essentially nonimmunogenic, even when delivered in excess of therapeutic dose [64] . However, aptamers are rapidly degraded in vivo and can be costly to generate, making commercialization and clinical translation difficult.
Summary and comparison of soluble cues
The induction and control of regenerative therapies can be influenced by a variety of soluble factors including small molecule drugs, polypeptides, and nucleic acids (Table 1) . Small molecule (chemical drugs) poses great potential for affordable regenerative therapies following research, development, and regulatory approval. Protein therapeutics, including growth factors ZFP-TFs, ZFNs, TALENs, and mABs, recently gained the opportunity for clinical use because of the advances in the industry of biotechnology and recombinant DNA technologies. Nucleic acid-based therapeutics can be generated using chemical methods and offer another avenue for control of endogenous pathways and protein production. Delivery of cDNA encoding for in vivo expression of a specific gene or protein therapeutic can cause cells to express any protein or gene, including growth factors. However, all of the soluble factors listed suffer from rapid degradation and clearance from the body if they are not delivered directly to their site of action, hinging their efficacy on the success of their carrier.
Selection of the appropriate soluble factor will be highly dependent on the pathogenesis of the disease state being studied. First, one must ask if the need is chronic or acute. Chronic disease states may benefit most from the genome editing provided by nucleic acid-based drugs; whereas acute disease states may be best treated with more temporary soluble factors, such as protein-based drugs or SMDs. If the disease state necessitates increased expression of certain genes or proteins, the administration of SMDs, growth factors, ZFP-TFs, or cDNA should be considered. Alternatively, if inactivation of a gene or repression of the translation of a specific protein is needed, SMDs, ZFPs, TALENs, mABs, RNAi, or aptamers could all be considered. Table 1 highlights the pros and cons associated with each soluble factor, as well as its most common use for comparative analysis and selection.
Methods of delivery
Once the appropriate soluble factor has been identified for the pathogenesis being studied, the appropriate delivery vehicle must be chosen. Soluble factors may need to be delivered in many ways, from systemic administration to intracellular delivery. Systemic delivery is appropriate for systemic diseases, but is rarely the most attractive or effective option for regenerative medicine applications because soluble factors degrade rapidly without an efficient carrier. For localized tissue regeneration, the ideal therapeutic would have a controlled local delivery to limit toxicity and minimize the amount of drug needed to achieve a therapeutic effect. There are several approaches for controlled local delivery (Fig. 3) . Suspension in an implantable or injectable scaffold and immobilization on or inside of biomaterial constructs give the most common examples. For example, the drug can be chemically linked to the network of a hydrogel or covalently immobilized to the surface of a scaffold, such as an electrospun fibrous matrix [65, 66] . Scaffolding systems such as these provide the option of controlled release by varying the porosity and degradation rate. Particulate delivery systems such as micro-and nanoparticles have also emerged as useful delivery vehicles, since their size can be tailored to deliver the cargo of interest extra-or intracellularly. Viral vectors can be used to deliver and promote the expression of DNA-based therapeutics in vitro by the generation of genetically modified cells (GMC) or, less frequently, in vivo. Genetically modified cells can be used as carriers, typically following transduction or transfection with a gene encoding the protein of interest. These carrier systems are often combined to create an optimal release profile in the tissue of interest.
Scaffolds for delivery
Biomaterial scaffolds have received a great deal of attention in tissue engineering for both local and sustained release of soluble factors. Scaffolds can be constructed from a variety of materials; the most common of which are hydrogels [67] and electrospun fibers [68] . These scaffolds can be loaded with soluble factors and rationally designed to control release kinetics by altering construction material, topography, porosity, and degradation characteristics [69] . Scaffolds are unique carriers because their material composition, stiffness, and size can be designed to fill a three-dimensional defect space to further assist in regeneration. Scaffolds can also be modified to provide physical and chemical cues to the surrounding tissue by mimicking the ECM in construction, stiffness, and protein coatings [70] . Injectable hydrogels for spinal cord regeneration, resorbable nerve conduits, and electrospun fibers are common examples of drug eluting scaffolds [70] [71] [72] [73] . 
Hydrogels
Hydrogel is a network of hydrophilic polymers rendered insoluble in water but swollen due to physically or chemically interacting crosslinks (Fig. 3a) . Hydrogels are often used as drug delivery scaffolds in regenerative therapies because their mechanical properties and drug release kinetics can be easily tailored [74, 75] . Hydrogels can be constructed from biocompatible synthetic or natural polymers. Synthetic monomers include poly(vinyl alcohol), poly(ethylene glycol) (PEG), poly(N-isopropylacrylamide) (pNIPAAm), and polyacrylates such as poly(2-hydroxyethyl methacrylate), among others [76] . Biological materials include, but are not limited to, chitosan, agarose, collagen, alginate, fibrin, and hyaluronan [76] . Hydrogels are often designed to release soluble factors by undergoing conformational changes in response to small molecule drugs [77] , pathological metabolites [78, 79] , or physiological conditions including body temperature [80] and high or low pH environments [81] . Such stimuli sensing systems are referred to as "smart" hydrogels and are commonly used as drug delivery vehicles in regenerative medicine. For example, a hydrogel of poly(N-isopropylacrylamide-co-acrylic acid), a copolymer of acrylic acid and thermosensitive pNIPAAm, was used to deliver EGF and VEGF directly to the wound bed via pH sensitive release. Treated mice showed improved wound healing compared to those given with the same growth factors loaded in poly(D,L-lactide-co-glycolide) (PLGA) microspheres that were delivered within a collagen hydrogel. These data suggest that a wound-pH-responsive hydrogel can evoke a better healing response than a pHinsensitive delivery systems. Similarly, in tissue engineering applications, injectable smart or photopolymerizable hydrogels with a controllable sol-gel transition can be delivered to fill a defect and excrete pro-regenerative signals to cells [70] . Hydrogels can also be used to maintain smaller DDS at the site of injury that would otherwise rapidly disperse throughout the body due to their size, such as micro-or nanoparticles. For example, to treat retinal-blinding diseases that result from an inadequate supply of retinol, an alginate hydrogel was loaded with PLGA microparticles carrying retinoids and injected intravitreally in murine model [82] . This biphasic system achieved sustained release of 9-cis-retinol, a chemically synthesized SMD, causing improved visual function and retinal structure. Hydrogels are also used to encapsulate and deliver therapeutic cells [83] . A chitosan hydrogel scaffold containing a proangiogenic small molecule (DFO) was generated and loaded with hMSCs for delivery to ischemic tissues to facilitate neoangiogenesis [84] . Multimodal constructs such as these can better imitate natural processes and will likely continue to be at the forefront of this field. However, the body's response to the hydrogel, as well as induced structural variations undergone during any "smart" transitions, can alter porosity and delivery kinetics and must be considered when designing hydrogel delivery systems [85] . 
Electrospun fibrous scaffolds
Over the past two decades, electrospinning has become a popular fabrication technique for generation of nano-and microfiber scaffolds due to its simplicity and versatility to fine-tune the mechanical and mass transport properties of the scaffolds. Fibrous scaffolds have been hallmarked as biomaterial implants due to their high surface-to-volume ratio and tunable biomimicry [68] . Electrospun fibrous scaffolds have been applied towards a broad range of regenerative medicine applications, including dermal wound healing, skeletal muscle regeneration, nerve regeneration, and spinal cord regeneration [26, 72, 86, 87] . Soluble factors can be immobilized on the surface of fibers for local delivery to the site of interest (Fig. 3b) [65] . Further control of release kinetics can be achieved by encapsulation of the soluble factor within the fibers. There are two methods by which substances can be encapsulated inside electrospun fibers. The first is blending the substance with the polymer materials prior to spinning. In this process, the substance is dissolved in organic solvent along with the polymer; during the spinning process, the organic solvent rapidly evaporates, leaving the substance immobilized on the surface of the fibers [88] . Bone morphogenic protein-2 (BMP-2) dissolved in PLGA/hydroxylapatite prior to spinning generated homogenously loaded electrospun scaffolds with a sustained release of BMP-2 in vivo for bone regeneration [89] . However, this method often results in uneven distribution of the proteins within the fibers and is generally characterized by a burst-release response [88, 90] . The second method is the generation of core-sheath fibers by emulsion electrospinning or core-shell electrospinning. Emulsion electrospinning is a recently developed facile technique for the generation of core-sheath fibers, in which the spinning solution is replaced by a water-in-oil emulsion [91] . This method is commonly used to encapsulate a hydrophilic drug into a hydrophobic polymer shell [92] . Since the encapsulated factor may contact organic solvents in the emulsion, coaxial electrospinning is safer for protein delivery [93] . Coaxial electrospinning employs a dual needle apparatus where a soluble inner core solution is spun within a polymer solution shell [94] . Using this method, delicate proteins and even live cells that are sensitive to the organic solvents commonly used in electrospinning can be suspended within the inner aqueous phase of hollow polymer fibers [95] . The release of these bioactive agents can be modulated by increasing the flow rate of the inner solution so that the core is larger and the shell thinner, or by including porogens in the shell such as PEG [96] . In a combinatorial study, coaxial electrospun polyurethane scaffolds including PEG as a porogen were loaded with VEGF and platelet-derived growth factor (PDGF) then seeded with factor VIII expressing skeletal myoblasts to treat hemophilia A in mice [87] . Induction of angiogenesis with VEGF and PDGF facilitated improved delivery of factor VIII throughout the bloodstream in vivo and improved clotting time to clinically relevant levels.
Particulates Micro-and nanoparticles are highly used for protein and SMD delivery as well as the nonviral delivery of nucleic acids (see Sect. 3.2.2) [97] . Micro-and nanoparticle carriers are separated based on their size; microparticles have a diameter in the micron range and nanoparticles in the submicron range (Fig. 3c) . A variety of materials can be used to generate these carriers. Liposomes, micelles, dendrimers, and hydrogels are common particulate systems used to carry soluble factors that can be generated in the nano to micron size range. Liposomes are lipid carriers that have an outer lipid bilayer and an inner aqueous space for soluble factors (Fig. 3c.1-upper) . Micelles are self-assembling lipid monolayers with a hydrophobic core and hydrophilic shell, making them useful for insoluble cargo such as some SMDs (Fig. 3c.1-lower) . Dendrimers have branched monomer units that soluble factors can be conjugated to for targeted and controlled delivery ( Fig. 3c.2 ). Hydrogels are both hydrophilic and tunable in chemical composition, making them a suitable micro-vehicle for soluble factor delivery (Fig 3c.3) . However, precise size control when generating these particulates remains an issue in the field [98] .
Carrier size has a large impact on drug delivery kinetics because the surface-to-volume ratio is inversely proportional to the radius of the particle. Microparticles do not cross most biological barriers, but particles less than 10 μm can be taken into cells by phagocytosis [99] . Microparticles are most successful when injected at the site of interest and have a tendency to stay in the general area where they are injected for weeks. For example, local injection of VEGF-loaded microspheres has been used to induce angiogenesis in vivo in murine hind limb ischemia [100] . On the contrary, nanoparticles are capable of traversing biological barriers and cellular membranes but can be cleared by the body in a matter of days [99] . For example, when vascular smooth muscle cell (VSMC) targeted the liposomes, with diameters between 100-400 nm, they were delivered intravenously to prevent restenosis in injured blood vessels; those not successfully delivered to VSMCs were found accumulated in the liver and spleen, suggesting clearance by the reticuloendothelial system [101] . Nano-and microcarriers can encapsulate a number of biomolecular cues and be tailored to release their cargo in response to certain stimuli such as temperature, light, pH change, or small molecule administration.
Carriers for nucleic acids
The delivery of intact nucleic acids in vivo is difficult because naked nucleic acids are rapidly cleared and degraded in the extracellular environment. Nucleic acids can be delivered to the cell nuclei in vivo or in vitro using viral transduction and nonviral transfection methodologies. In vivo DNA delivery is the most complex, as researchers have the least control over which cells are transfected/transduced. Because of this lack of control, in vivo delivery can be associated with high health risks, especially with the risk of insertional mutagenesis using viral delivery. Viral DNA delivery boasts high transfection efficiency, but poses safety concerns stemming from immunogenicity, toxicity, and untargeted DNA insertion. Nonviral vectors offer transgene expression without immunogenic integrating carriers; but the efficiency of nonviral delivery must be increased before it can be successful in regenerative therapies. Although nonviral DNA delivery boasts a decreased risk for insertional mutagenesis when compared to integrating viral DNA delivery, the risk still exists. Even a small risk for insertional mutagenesis will make DNA delivery difficult to translate into clinical use.
Viral vectors for nucleic acid delivery
Viral gene delivery has been studied using the following three main viruses: adenovirus (AV), adeno-associated virus (AAV), and retro/lentivirus (RV/LV) (Fig 3d) . Both AV and AAV lead to transient expression, while RV/LV gives permanent gene expression. AV is highly immunogenic when used in multiple doses in vivo, as such their primary application lies in transient therapeutic application or ex vivo modification of T cells for immunotherapy. AAV does not integrate its DNA cargo into the genome, but can achieve prolonged expression as an episomal vector. AAV has recently had success in treatment of blindness, hemophilia, and muscular dystrophy [102, 103] . Lentivirus and retrovirus are unique in that they integrate their cargo into the host genome for long-term expression. In some cases, this insertion takes place within important endogenous genes and can result in gene activation. The random insertion of viral DNA into the host genome resulting in unwanted mutation is referred to as insertional mutagenesis. In 2003, a clinical trial was conducted to treat patients with severe immunodeficiency using gene therapy with retroviruses. Four years after, success had been proclaimed; insertional mutagenesis caused accidental gene activation in 5 of the 17 cured patients resulting in leukemia [104] . Because of the dangers associated with viral gene delivery, nonviral delivery has become a major focus of research in the fields of drug delivery and regenerative medicine.
Nonviral methods for nucleic acid delivery
Nonviral gene transfer does not integrate the exogenous gene into the host genome, and the risk of insertional mutagenesis drops drastically. Nonviral gene delivery can be conducted in vitro via direct injection of a plasmid (circular DNA construct) into a cell, membrane poration, or complexation of plasmid DNA (pDNA) with carriers such as lipids (lipofection) (Fig.3f.2 ) [105] , particulates (Sect. C.2) [106] , or cationic polymers (Fig.3f.3) [107, 108] . Nonviral DNA delivery can be carried out in vivo when using the appropriate carrier to prevent degradation and enhance endosomal escape once endocytosed into the cell [109] . To date, the muscle is the only tissue where direct injection of naked pDNA has been show to successfully lead to gene transfer, although the level of transgene expression is generally deemed too low to be therapeutic [110] .
Nonviral vectors, although achieving only transient and low gene expression levels, compensate with their ease of synthesis, low immunogenicity, and unrestricted plasmid size [111, 112] . They have the potential to be administered repeatedly with minimal host immune response. Nonviral vectors also face less of a challenge than viral vectors in addressing pharmaceutical issues such as scale-up, storage, stability, and quality control. Numerous studies have investigated the use of cationic polymers or cationic lipids to form nanocomplexes with pDNA, known as polyplexes and lipoplexes, respectively (Fig. 3f.1, f.2) . Lipopolyplexes, the product of lipid-polymer-DNA complexation, leverage on the advantages of a cationic polymer and a lipid to formulate a DNA-polymer core in a lipid shell (Fig. 3f.3 ) [113] .
Polyplexes, lipoplexes, and lipopolyplexes all serve to protect the DNA from enzymatic degradation during transit from the extracellular space to the nucleus of the cell. However, the DNA must be released from these nanocomplexes for transcription to take place. Finding the balance between tight packing extracellularly and efficient unpacking intracellularly has been a challenge to effective nonviral gene delivery [114, 115] . Polymeric gene carriers enjoy the advantage of versatility to address this balance. Rigidity, hydrophobicity/hydrophilicity, charge density, biodegradability, and the molecular weight of the polymer chain are all parameters that can be adjusted to achieve an optimal complexation with DNA. Versatility is important in view of the broad range of regenerative medicine applications and their unique demands. It is likely that for different tissues, or different routes of administration in vivo, the desirable characteristics of the DNA nanocomplexes would differ. A powerful approach to identify the optimal nonviral carrier for different applications is to use the combinatorial synthesis to generate a large number of candidates for high-throughput screening against the cell type of interest. Both polyplex and lipoplex development have greatly benefited from this approach [116] [117] [118] . The caveat is that in vitro and in vivo correlation remains imperfect; the best carriers identified in vitro by the combinatorial approach may not be optimal for in vivo applications.
Genetically modified cells as carriers
Cells that have been genetically modified to express a gene or protein of interest can be used to produce protein-and nucleic acid-based soluble molecules in vivo (Fig. 3e) . Any cell type can be modified in this way, including stem cells and adult differentiated cells from either allogenic (from the same species) or autogenic (from the same person) sources. Allogenic cell sources risk immune response from the patient, but have an advantage in regenerative medicine because they can be shelf-ready for use in the operation room. In an autologous system, a patient's own cells are removed, modified ex vivo, and readministered to regenerate tissues in the diseased site, obviating the risk of an immune response. Genetic modification of a patient's own cells allows for autologous therapeutics, but the cost involved with harvesting, purifying, genetically modifying, and implanting each individual patient's cells is a concern when considering commercialization. GMC are commonly implanted on a scaffolding system or injected in a hydrogel suspension because freely injected cells typically diffuse away from the injection site prior to integration with the host tissue [119] . Delivering cells as carriers of the therapeutic soluble factors offers a unique two-pronged technique for treatment of degenerative diseases by increasing cell number at the defect with cells that secrete pro-regenerative soluble factors [120] . However, cellular replacement therapies such as these rely on the sourcing of correct cell type, as well as the retention of delivered cells at the site of the defect.
Within the last decade, gene delivery has generated two new genetically modified cell types that have shown great promise as cellular carriers for regenerative therapeutics as follows: induced pluripotent stem cells (iPSCs) and transdifferentiated cells. With the advent of iPSCs and transdifferentiation techniques, new methods of cellular therapy using patient-specific cells may become a reality. Since iPSCs display pluripotency, the ability to differentiate into any cell type within the body, and can be derived from any tissue at any age, the ethical, sourcing, and political issues amongst researchers, and the public that arose when dealing with human embryonic stem cells can be avoided. iPSCs and transdifferentiated cell types provide the option for ex vivo reprogramming and generation of patient-specific cellular therapeutics for regenerative medicine.
Induced-pluripotent stem cells
iPSCs are fully differentiated somatic cells that have been reprogrammed to a pluripotent state by overexpression of specific transcription factors (TFs). This method was recently reported in 2006, when adult murine fibroblasts were dedifferentiated to pluripotent stem cells using viral delivery of genes encoding for specific TFs [4] . As such, the cellular processes that mediate this conversion are not yet fully understood. iPSCs are currently being used for disease modeling and drug discovery [9] . Because of their pluripotency, iPSCs have great therapeutic potential. However, with pluripotency comes the risk for teratoma formation, which gives reason for concern when considering iPSCs as cellular therapies in humans. iPSC could soon be used in clinical trials in Japan; the success or failure of these trials, the first to be performed in humans, will have a massive impact on the future of iPSCs as cellular therapeutics [121] .
Transdifferentiation
Transdifferentiation, where an adult cell is directly converted into another adult cell type without passing through a pluripotent stage, presents a novel approach to generating cells for patient-specific implantation. The process for generating transdifferentiated cell types is very similar to that of generating iPSCs. It is typically carried out by DNA transfection or protein-based procedures. Researchers have successfully converted fibroblasts into cardiomyocytes [122] and neurons [123] , with the long-term goal of generating functional cells for cellular therapies. Transdifferentiation differs from reprogramming and iPSCs because it offers an opportunity to convert cells directly across distinct linage barriers. Since cells do not have to spend time in a pluripotent state during the conversion process across linages, transdifferentiation avoids the possibility of teratoma formation and offers a one-step conversion to the final cell type of interest. However, transdifferentiation efficiency remains a barrier to this technology, with efficiency of reprogramming often hovering only a few percent above the starting number of cells [124] .
Carrier selection
In this section, a variety of delivery systems used in regenerative medicine, each with unique properties and drawbacks, have been described. It is important to select the correct delivery system based on the soluble factor and disease pathogenesis (Fig. 4) . One must consider where the soluble factor is active; does it need to be delivered extracellularly (SMD), intracellularly (siRNA, mRNA), or to the nucleus (pDNA)? Size and specificity of the carrier are important factors in this consideration and for biodistribution. Nanoparticles and viral delivery often have the most success for intracellular delivery, while 3-D scaffolds, microparticles, and GMCs are primarily used for extracellular delivery. The nature of disease pathogenesis, what biological tissue or cell population the soluble factor must reach, will also influence the carrier selection. In the case of regenerating a tissue defect, an implantable or injectable 3-D scaffold system with or without GMCs may be optimal. Intravenous or direct injection of targeted particulates carrying protein or nucleic acid cues would be ideal for a systemic or localized pathogenesis.
When selecting a carrier, one should pose the question: do the physical and chemical traits of the carrier alone have therapeutic effects in the absence of the delivery of soluble factors? Environmental cues from the ECM and soluble factors directly affect cell morphology, proliferation, and differentiation [125] . Carriers can mimic the material composition of the ECM by using naturally derived biomaterials such as collagen and constructing the carrier as a porous micro-or nanoscale scaffolding structure to promote cellular ingrowth [126] . For example, collagen sponges with pore sizes 100±50 μm filled with collagen hydrogel aided in bone reconstruction and cellular infiltration when implanted into periodontal defects in dogs [127] . Also, hollow collagen nerve conduits have had clinical success and are manufactured for peripheral nerve defects less than 3 cm in length by companies such as Stryker and AxoGenic [128] . These results show that the cues cells received from scaffold composition and physical characteristics aided in tissue regeneration. Although tubular nerve guides can promote axonal elongation over short gaps, the inclusion of cells, drugs, electrospun fibers, or hydrogel fillers within the guide can significantly improve regeneration [129] . Polymer scaffold conduit permeability has been shown to alter nerve regrowth [130] . Physical characteristics including diameter and 3-D orientation of electrospun fibers within nerve guides has also been shown to affect nerve regrowth [72, 131, 132] . The fibrous nature of electrospun scaffolds may provide topographical cues to the adherent cells that mimic the structure of the native ECM.
One should also consider carrier charge when designing carriers for negatively charged soluble factors, such as nucleic acids; but does charge alone have an effect? The use of charged nerve guides, such as carbon nanotubes (CNT), has recently shown promise in improving neural regeneration. CNTs have been shown to improve the responsiveness of neurons by forming tight contacts with the cell membranes; this interaction is thought to favor electrical shortcuts between the proximal and distal compartments of the neuron [133] . Since cells glean cues from the carrier as well as the soluble factor being delivered, the characteristics of the carrier should be chosen logically to enhance the success of the regenerative therapy. With a combinatorial approach using soluble factors delivered by rationally designed carriers and scaffolds, regenerative technologies will become a more prominent feature in clinical medicine.
Modulating angiogenesis in regenerative medicine
Blood vessel growth is a complex process and presents one of the largest barriers to tissue engineering. However, the controlled delivery of soluble factors can be used to stimulate this process in vivo or enhance it in tissue-engineered implants [134] . Blood vessels deliver oxygen, nutrients, and metabolites to tissues and clear waste away from sites of inflammation. As such, a lack of vasculature will lead to tissue necrosis. Directed formation of microvasculature requires precise control and coordination of cells with their environment. Because of this complexity, the largest clinical successes in tissue engineering have been achieved in tissues that do not require intricate vasculature, such as the bladder and non-load-bearing cartilage [135] [136] [137] .
Blood vessel growth is characterized by the following two processes: angiogenesis, the formation of blood vessels from preexisting blood vessel populations; and vasculogenesis, the formation of blood vessels without the presence of existing vasculature [138] . Vasculogenesis primarily occurs during fetal development of the circulatory system, but is also seen during tumor growth. During vasculogenesis, endothelial precursor cells migrate and differentiate in response to cues, such as growth factors and the surrounding ECM, to form new blood vessels. In contrast, during angiogenesis, the existing blood vessels split or sprout to form new blood vessels. There are three major types of blood vessels as follows: arteries, capillaries, and veins. Arteries carry blood away from the heart and are multilayered structures consisting of an outer layer of connective tissue, intermediate layer of fibroblasts, and inner layer of endothelial cells. Arteries carry oxygen and nutrients through the body to reach capillaries that will facilitate their delivery to surrounding cells and tissues. Capillaries 4 Carrier selection guide. Selection of the correct delivery vehicle must first consider whether the soluble factor is active intracellularly, or if extracellular delivery is optimal. Once delivery method is chosen, the delivery method of the carrier should be selected based on disease pathogenesis. Injection of microscopic carriers may be optimal for systemic or localized pathogenesis, while implantation of 3-D scaffold carriers are most effective when repairing a tissue defect are responsible for the exchange of water and chemicals between blood vessels and tissues. Finally, veins carry blood from capillaries back to the heart. Successful angiogenesis requires a complex cascade of events including endothelial cell (EC) activation, migration, and proliferation, followed by EC arrangement into immature vessels, addition of pericytes and smooth muscle cells (SMCs), and deposition of ECM as the vessels mature [139] . Vascular endothelial growth factor (VEGF) and fibroblast growth factor are heparin-binding growth factors that are involved in the initiation of angiogenesis and induction of EC proliferation and migration. Platelet-derived growth factor B (PDGF-B) recruits pericytes and SMCs, while transforming growth factor beta causes ECM deposition of laminin and collagen types I and IV to give new vessels stability [140] . In some diseases such as cancer, diabetic angiopathy, and AMD, leaky blood vessels contribute to disease pathogenesis, and antiangiogenic therapeutics must be developed. Pigment epithelium-derived factor (PEDF) is a multifunctional secreted protein that has been shown to be a potent inhibitor of neoangiogenesis [141] .
There are many groups working to modulate angiogenesis in vivo by the delivery of small molecule drugs [142] , growth factors [143] , or nucleic acids [144, 145] . Readers are directed to recent and more detailed reviews on the use of protein [146, 147] and nucleic acid [148, 149] delivery systems for the modulation of angiogenesis [150] [151] [152] . Delivery of these soluble factors using synthetic or biologic DDS presents a new wave in regenerative therapeutics moving towards clinical translation. This is evidenced by the FDA opening a new regulatory division, the office of combination products, in 2002 to analyze complex drug and cell delivery systems for regenerative medicine. Angiogenesis of nonhealing wounds and antiangiogenesis in the treatment of AMD are examples of clinical applications, in which soluble factor delivery can be used to control blood vessel growth.
Promoting angiogenesis in nonhealing wounds by nucleic acid delivery Chronic nonhealing wounds are a major medical problem that affect millions of Americans annually and cost billions of dollars per year [153] . There are several different causes of nonhealing wounds including decubitus ulcers, venous stasis ulcers, arterial insufficiency ulcers, and diabetic foot ulcers (DFU). DFU develop in 15 % of people with diabetes, and 14 to 20 % of them require amputation [153] . A leading cause of DFU is vascular insufficiency [154, 155] ; thus, application of pro-vasculogenic scaffolds, introduction of GMCs, or delivery of proangiogenic factors is likely to improve DFU care. At the time of this writing, there is only one registered study on clinicaltrials.gov (a completed Phase I study), where a drug delivery matrix has been applied to DFU. In the study, an adenoviral vector carrying the DNA encoding for PDGF-B was incorporated into a collagen matrix for application to DFU [156] . The study revealed that the bovine type I collagen matrix, termed gene-activated matrix (GAM), could deliver the PDGF-B gene to invading cells to produce the protein at the wound site for a sufficient period of time [157] . The data leading to this clinical trial came from preclinical in vivo studies, where a PDGF-B encoding adenovirus delivered via the GAM was found to enhance granulation tissue deposition and epithelialization in a rabbit model. The vector DNA and transgene mRNA were found within wound beds as late as 28 days posttreatment, and a single application of the biologic scaffold was equivalent to repeated applications of the PDGF-B protein [158] . Cardium Therapeutics, which owns the technology, is using GAM as a new product platform to deliver advanced wound care and therapeutic products including anti-infectives, antibiotics, peptides, proteins, small molecules, DNA, and GMCs.
Inhibiting angiogenesis to prevent age-related macular degeneration
In contrast to DFU, where there is a lack of angiogenesis, agerelated macular degeneration is caused by excessive blood vessel formation. AMD is the leading cause of legal blindness in people older than 55 years in the US, affecting more than 1.75 million Americans. In the wet form, newly formed abnormal blood vessels grow under the center of the retina. These faulty vessels leak blood and scar the retina, eventually destroying central vision of the patient. As of the writing of this manuscript, there are six studies listed on clinicaltrials.gov under the search terms "macular degeneration" and "drug delivery" and "angiogenesis". In one phase I study, AdGVPEDF.11D was given as an openlabel, single administration, dose to 28 patients with wet AMD to determine safety [159] . AdGVPEDF.11D, a replication deficient AV vector containing the gene for the antiangiogenic PEDF protein, was delivered once via intravitreal injection into one eye. Investigators observed positive changes in vision and retinal appearance at the higher dose cohorts in some patients; no dose limiting toxicities or drug-related severe adverse events were reported [160] . The study sponsor GenVec believes that early intervention therapy with AdGVPEDF.11D holds the promise to stabilize or improve vision in patients with AMD. Their hypothesis is supported by preclinical investigations, where they found that AdPEDF rapidly elevates intraocular PEDF protein levels, inhibits abnormal blood vessel growth, and causes abnormal blood vessel regression.
Future of regenerative medicine and pathway to the clinic
The first steps to translating a regenerative medicine technology are as follows: identifying an unmet medical need and developing a hypothesis, explaining how new technology might alter disease pathogenesis (Fig. 5 step 1 : disease pathogenesis). To be successful in this first step, it is critical to understand normal biology, have a perspective of what models are used to study the disease, and lastly, to understand the mechanism of action as it relates to the disease process. The next step in the process is to analyze the competitive commercial landscape and consider how the disease is currently managed in the clinic. Consider how and why the technology would be better than existing therapies for the specific disease ( Fig. 5 step 2 : current treatments). Examples of how the technology could improve patient care are enhanced effectiveness, cost benefits, or reduced toxicity. Translating the technology should also be patentable. Without patent protection, commercialization will be difficult, if not impossible. Patent protection ensures the investor(s) will have financial security and enables them to assume financial risks inherent in running clinical trials. The next step (Fig. 5 step 3: proof-of-concept testing) is to test the technology in the appropriate preclinical in vitro, small and large animal models capable of predicting success in humans. Animal models of human disease vary in their accuracy in predicting human response. Upon successful completion of animal studies, meetings with the FDA will guide the subsequent steps in development, including standardized testing for safety, toxicity, and effectiveness ( Fig. 5 step 4: FDA preclinical testing) . Once the FDA is satisfied that appropriate preclinical studies have been completed, human clinical trials may commence (Fig. 5 step 5 : clinical testing in humans). There are four phases of clinical trials. Phase I trials are the first stage of testing carried out in human subjects and emphasize safety. They are designed to assess the drug's most frequent and serious adverse events, as well as how the drug is metabolized and excreted. Phase II trials evaluate the effectiveness, shortterm side effects, and common risks associated with the drug.
Phase III trials obtain information on the effectiveness of the drug across different populations, dosages, and in combination with other drugs. Upon successful completion of phase III clinical trials, technologies can be commercialized for use in humans. Phase IV is often referred to as post-marketing surveillance. In this period, the ongoing safety and efficacy of the drug is monitored in large populations, and additional uses of the drug are identified that might be approved by the FDA. In summary, following this simplified 6-step process, researchers and clinicians can develop therapies that translate into improved patient care (Fig. 5 step 6 : clinical outcomes).
Conclusion
With a combinatorial approach using soluble factors delivered by rationally designed carriers and scaffolds, regenerative technologies will become a more prominent feature in clinical practice and regenerative medicine. SMDs have only recently been developed for applications in regenerative medicine; however, the identification and optimization of new SMDs is a slow, laborious, and costly process limiting their development. Polypeptide and nucleic acid-based therapeutics likely represent the future of this field. Clinical success has already been seen with mABs and aptamers, and there are ongoing clinical trials using growth factors, cDNA, and RNAi technologies for regenerative medicine. Genome editing using ZFPTFs, ZFNs, and TALENs represents an exciting direction in regenerative therapeutics that is still in its infancy.
Development of these technologies for regenerative medicine will require continued multidisciplinary research and an understanding of the regulatory pathways that will lead to clinical success. Recent progress in this field suggests that bioengineered delivery of soluble factors for regenerative medicine will have expanded clinical applicability in the future. This field represents an exciting collaborative effort between basic scientists developing therapeutic soluble factors, biomedical engineers improving their delivery, and clinicians driving and translating the technologies in the clinic. Regenerative medicine has the potential to drastically change the field of health care from reactive to preventative and restorative. Step Step 3 Proof-ofConcept testing
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